Quick Answer
ENANTA PHARMACEUTICALS INC reported R&D Expense of $106.74 million for fiscal year 2025.
ENANTA PHARMACEUTICALS INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $106.74M | -18.8% |
| 2024 | $131.48M | -19.6% |
| 2023 | $163.52M | -0.6% |
| 2022 | $164.52M | -5.5% |
| 2021 | $174.11M | +27.3% |
| 2020 | $136.76M | -3.8% |
| 2019 | $142.21M | +49.9% |
| 2018 | $94.86M | +65.1% |
| 2017 | $57.45M | +42.0% |
| 2016 | $40.46M | +74.5% |
| 2015 | $23.19M | +23.7% |
| 2014 | $18.74M | +11.3% |
| 2013 | $16.84M | +11.4% |
| 2012 | $15.12M | +30.9% |
| 2011 | $11.55M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $20.86M | -24.6% | -23.3% |
| June 30, 2025 | $27.21M | -5.3% | -3.0% |
| March 31, 2025 | $28.07M | -21.1% | +1.5% |
| December 31, 2024 | $27.66M | -24.0% | -3.8% |
| June 30, 2024 | $28.74M | -33.1% | -19.2% |
| March 31, 2024 | $35.59M | -18.1% | -2.2% |
| December 31, 2023 | $36.37M | -11.1% | -15.4% |
| June 30, 2023 | $42.99M | +10.0% | -1.1% |
- ENANTA PHARMACEUTICALS INC showed a decrease of -18.8% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2025 period, ENANTA PHARMACEUTICALS INC’s r&d expense has grown by 824.4% (from $11.55 million to $106.74 million).
- The most recent figure is from ENANTA PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on November 19, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: